SearchSkip to Search Results
- 1Bladder cancer
- 1Epigallocatechin gallate
- 1Hepatitis C virus
- 1Liver transplantation
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder CancerDownload
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
Novel Agents Inhibiting Hepatitis C Virus; Application to Prevention of Re-infection after Liver TransplantationDownload
Recurrent Hepatitis C virus infection drives inferior outcomes experienced by patients undergoing liver transplantation due to HCV-associated liver disease. Existing therapies exhibit increased toxicity, poor efficacy, and profound patient intolerability in the immediate transplantation period....
Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers : Implications in cancer chemo- and immunotherapyDownload
Signal Transducer and Activator of Transcription 3 (STAT3), a common oncogenic mediator, is constitutively activated in many types of human cancers and plays a critical role in tumor growth and cancer immune evasion. The focus of this dissertation is the delivery of STAT3 inhibitor cucurbitacins...